ChemMedChem
Scope & Guideline
Exploring the nexus of chemistry and pharmacology.
Introduction
Aims and Scopes
- Medicinal Chemistry and Drug Design:
The core focus is on the design, synthesis, and evaluation of new chemical entities with potential therapeutic applications, particularly in oncology, infectious diseases, and metabolic disorders. - Biological Evaluation and Mechanistic Studies:
Research often includes evaluation of biological activities of compounds, exploring mechanisms of action, and understanding structure-activity relationships (SAR) to optimize therapeutic efficacy. - Nanomedicine and Drug Delivery:
The journal publishes studies on novel drug delivery systems, including nanoparticles and nanocarriers, aimed at enhancing the bioavailability and targeted delivery of therapeutic agents. - Natural Products and Synthetic Derivatives:
Research related to the isolation, modification, and pharmacological evaluation of natural products and their synthetic derivatives is a prominent theme, highlighting their potential as drug candidates. - Chemical Biology and Target Identification:
ChemMedChem includes work on the application of chemical tools to elucidate biological pathways, identify drug targets, and develop new therapeutic strategies. - Innovative Analytical Techniques:
The journal encourages the use of advanced analytical techniques such as molecular modeling, high-throughput screening, and various spectroscopic methods to aid drug discovery.
Trending and Emerging
- Targeted Therapy and Precision Medicine:
Recent publications highlight a growing interest in targeted therapies and precision medicine approaches, focusing on personalized treatment options based on genetic and biomolecular profiling. - Proteomics and Targeted Protein Degradation:
The use of proteomics to identify new drug targets and the development of PROTACs (Proteolysis Targeting Chimeras) for targeted protein degradation are gaining traction, showcasing innovative strategies for drug discovery. - Drug Repurposing Strategies:
There is an increasing trend towards drug repurposing, particularly in the context of emerging diseases such as COVID-19, where existing drugs are evaluated for new therapeutic applications. - Nanotechnology in Therapeutics:
The integration of nanotechnology in drug delivery systems, including the use of nanomaterials for enhanced therapeutic efficacy and imaging, is a rapidly expanding area of interest. - Artificial Intelligence and Machine Learning in Drug Discovery:
The application of AI and machine learning techniques for predictive modeling, compound screening, and optimizing drug design processes is becoming increasingly prominent in recent publications. - Hybrid Molecules and Multitarget Agents:
Research on hybrid molecules that combine multiple pharmacophores or target multiple pathways is on the rise, reflecting a shift towards more complex and effective therapeutic agents.
Declining or Waning
- Traditional Small Molecule Antibiotics:
Research on traditional small molecule antibiotics has decreased, possibly due to a shift towards exploring novel mechanisms of action and the use of combination therapies to combat antibiotic resistance. - Single-Target Therapeutics:
The focus on single-target drug design has waned in favor of multitarget approaches, reflecting a growing understanding of the complexity of diseases and the need for holistic treatment strategies. - In vitro Studies without in vivo Validation:
There is a noticeable decline in standalone in vitro studies that lack in vivo validation, as the field increasingly emphasizes translational research that bridges laboratory findings with clinical relevance. - Basic Chemistry without Biological Context:
Papers that focus purely on synthetic methodologies without direct applications in medicinal chemistry or biological evaluation have seen a reduction, as the journal prioritizes research with clear therapeutic implications.
Similar Journals
MOLECULAR DIVERSITY
Unveiling Innovations in Molecular DiversityMOLECULAR DIVERSITY, published by Springer, stands as a pivotal platform within the fields of chemistry, biology, and pharmacology since its inception in 1995. This esteemed journal aims to foster interdisciplinary research and innovation, particularly in areas such as catalysis, drug discovery, inorganic and organic chemistry, and molecular biology. With a diverse scope that reflects contemporary scientific challenges, it has been recognized for its significant contributions, boasting commendable Scopus rankings and an impact factor that underscores its relevance in critical fields. Although not an open access journal, MOLECULAR DIVERSITY continues to influence and engage researchers, professionals, and students alike by providing a forum for high-quality peer-reviewed articles and cutting-edge research findings. As it converges years of scientific dynamism from 1995 to 2024, this journal remains vital for those advancing the frontiers of molecular science and engineering.
CHEMICAL & PHARMACEUTICAL BULLETIN
Empowering researchers with pivotal findings in drug discovery.CHEMICAL & PHARMACEUTICAL BULLETIN, published by the Pharmaceutical Society of Japan, has been a cornerstone in the fields of chemistry, drug discovery, and medicine since its inception in 1958. With an ISSN of 0009-2363, this esteemed journal offers a platform for the dissemination of innovative research and critical insights contributing to these dynamic disciplines. Housed in Tokyo, Japan, it is strategically poised to bridge the gap between chemical sciences and pharmaceutical applications. Although the journal operates under a traditional subscription model and does not currently offer open access, it maintains a solid reputation, evidenced by its Q3 category rankings in multiple relevant fields and its percentile positions in Scopus, specifically 48th in General Chemistry and 30th in Drug Discovery. Researchers, professionals, and students alike will find invaluable resources within its pages, as it diligently covers shifting paradigms and emerging methodologies critical to advancing both theoretical understanding and practical applications in the pharmaceutical realm.
CURRENT MEDICINAL CHEMISTRY
Driving Progress in Chemical and Pharmaceutical Research.Current Medicinal Chemistry is a leading journal published by Bentham Science Publishers Ltd, known for its rigorous focus on the multifaceted realm of medicinal chemistry. With an ISSN of 0929-8673 and E-ISSN 1875-533X, the journal plays a crucial role in disseminating high-quality research findings that bridge the gap between chemistry and health sciences. Operating from Sharjah, United Arab Emirates, it has been a prominent scholarly resource since its inception in 1994, and is expected to continue until 2024. Current Medicinal Chemistry has earned its place in the academic community with an impressive impact factor and categorization in Q1 and Q2 quartiles across various disciplines, including Organic Chemistry, Biochemistry, Drug Discovery, and Pharmacology, highlighting its substantial contribution to these fields. Notably, it ranks 24th in Organic Chemistry and is within the 88th percentile, underscoring its appeal to researchers, professionals, and students alike who are keen on exploring cutting-edge advancements in drug design and development. Although it is not an open-access journal, it provides vital content that informs and inspires innovation in medicinal chemistry, appealing to a global audience committed to enhancing human health through scientific discovery.
CURRENT DRUG TARGETS
Illuminating Pathways in Clinical BiochemistryCURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.
JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH
Illuminating Paths in Analytical Chemistry and BeyondJOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH is a prestigious publication in the field of natural products, focusing on valuable research spanning analytical chemistry, pharmacology, and complementary medicine. Published by Taylor & Francis Ltd in the United Kingdom, this journal has established itself as a key resource for academics and professionals seeking to explore advancements in drug discovery and organic chemistry. With a converged publication timeline from 1998 to 2024, the journal boasts several commendable category quartiles as of 2023, reflecting its robust standing in the research community: Q2 in Complementary and Alternative Medicine, Q3 in multiple domains including Analytical Chemistry and Organic Chemistry, and Q4 in Molecular Medicine. Although it currently does not offer open access, the journal remains a valuable compendium for empirical research and innovative studies in areas such as pharmacology and medicinal chemistry. Researchers, professionals, and students alike will find the JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH to be an essential platform for sharing groundbreaking findings and fostering collaborations that lead to significant advancements in science and health.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
Leading the Charge in Enzyme ResearchJOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, published by Taylor & Francis Ltd, is a premier open-access journal that has been at the forefront of research in the field of medicinal chemistry since its inception in 1985. With an ISSN of 1475-6366 and an E-ISSN of 1475-6374, this journal boasts a prestigious reputation reflected in its impressive Q1 rankings across critical categories such as Drug Discovery and Pharmacology as of 2023. Situated in the United Kingdom, it plays a vital role in disseminating high-quality research that addresses the burgeoning needs of drug discovery and enzyme inhibition methodologies. The journal supports full open access, providing a platform for researchers, professionals, and students to share significant findings and innovations widely. With a robust impact factor, the JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY is indispensable for any academic or professional involved in the pharmacological sciences, offering an unparalleled insight into the latest advancements in therapeutic strategies and drug development.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
Elevating Drug Development Through Rigorous ResearchCOMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING is an esteemed journal published by Bentham Science Publishers Ltd, focusing on the rapidly evolving fields of combinatorial chemistry and high-throughput screening. With ISSN 1386-2073 and E-ISSN 1875-5402, this journal provides a critical platform for researchers, professionals, and students engaged in the development and application of novel methodologies aimed at drug discovery and organic chemistry. Since its inception in 1998, the journal has consistently contributed valuable insights, achieving a respectable 2023 Category Quartile Ranking of Q3 across relevant categories including Computer Science Applications, Drug Discovery, and Organic Chemistry. Although it does not currently provide open access options, its rigorous peer-review process and commitment to scientific excellence enhance its reputation in the academic community. Researchers can leverage this journal's findings to stay at the forefront of advancements in their fields, making it an essential resource for anyone dedicated to innovation in chemistry and related disciplines.
TETRAHEDRON LETTERS
Exploring the Nexus of Drug Discovery and ResearchTETRAHEDRON LETTERS, published by Pergamon-Elsevier Science Ltd, is a leading journal in the fields of Biochemistry, Drug Discovery, and Organic Chemistry, with a rich legacy since its inception in 1959. This prestigious journal serves as a vital resource for researchers and professionals dedicated to advancing the understanding of chemical sciences, featuring high-impact research that influences both academic and practical applications. Although it is currently classified in the third quartile across its categories for 2023, its rigorous peer-review process ensures the publication of quality research that contributes to the scientific community. With an ISSN of 0040-4039 and an E-ISSN of 1873-3581, TETRAHEDRON LETTERS is easily accessible for those in the academic landscape seeking to stay abreast of innovative developments. Researchers, professionals, and students alike will find invaluable insights and collaborative opportunities within the pages of TETRAHEDRON LETTERS, making it an essential read for anyone involved in the chemical sciences.
Future Journal of Pharmaceutical Sciences
Exploring the Future of Drug Science and Healthcare SolutionsThe Future Journal of Pharmaceutical Sciences, published by Springer, stands as a vital resource in the realm of pharmaceutical research and innovation. Recognized for its open access initiative since 2015, this journal promotes extensive dissemination of cutting-edge discoveries, fostering collaboration among researchers, industry professionals, and students alike. With an ISSN of 2314-7245 and an E-ISSN of 2314-7253, it aims to bridge the gap between laboratory research and practical applications in the pharmaceutical sciences. Although specific metrics like HIndex and Scopus ranks are currently unavailable, the journal's commitment to high-quality, peer-reviewed content positions it as a promising platform for advancing pharmaceutical science. By engaging with this journal, contributors and readers can participate in the vibrant discourse shaping the future of drug development, therapeutic strategies, and healthcare solutions.
BIOORGANIC CHEMISTRY
Exploring innovative pathways in drug discovery.BIOORGANIC CHEMISTRY, published by Academic Press Inc., a prestigious imprint of Elsevier Science, represents a cornerstone in the fields of biochemistry, organic chemistry, and drug discovery. With an impressive Scopus rank placing it in the top quartiles across critical categories—including Q2 for Biochemistry and Drug Discovery, and Q1 for Organic Chemistry—this journal has established itself as a vital resource for researchers, professionals, and students alike. Featuring a diverse array of articles that explore innovative methodologies and emerging trends from 1971 to the present, BIOORGANIC CHEMISTRY effectively bridges the gap between laboratory research and practical applications. Although not an Open Access journal, its rigorous peer-review process ensures the delivery of high-quality, impactful research that drives advances in the understanding and application of biochemistry. With an aim to facilitate scientific discourse and collaboration, it invites contributions that further the exploration of chemical processes within biological systems.